Table 2. Chromosomal alterations of primary tumors from liver metastatic (n = 27) versus non-metastatic sCRC patients (n = 31).
| Liver metastatic tumors (n = 27) | Non-metastatic tumors (n = 31) | p-value | Total cases (n = 58) | |
| Chromosome 1 | ||||
| Normal | 7 (26%) | 14 (45%) | 21 (36%) | |
| del(1p) | 13 (48%) | 13 (42%) | NS | 26 (45%) |
| Polysomy | 7 (26%) | 4 (13%) | 11 (19%) | |
| Chromosome 7 | ||||
| Normal | 5 (19%) | 14 (45%) | 19 (33%) | |
| del(7q) | 5 (19%) | 1 (3%) | NS | 6 (10%) |
| q+ | 1 (3%) | 2 (7%) | 3 (5%) | |
| Polysomy | 16 (59%) | 14 (45%) | 30 (52%) | |
| Chromosome 8 | ||||
| Normal | 3 (11%) | 7 (23%) | 10 (17%) | |
| del(8p) | 5 (19%) | 4 (13%) | 9 (15%) | |
| q+ | 2 (7%) | 3 (9%) | NS | 5 (9%) |
| Del(8p)/8q+ | 12 (44%) | 8 (26%) | 20 (35%) | |
| Polysomy | 5 (19%) | 9 (29%) | 14 (24%) | |
| Chromosome 13 | ||||
| Normal | 7 (26%) | 13 (42%) | NS | 20 (35%) |
| Polysomy | 20 (74%) | 18 (58%) | 38 (65%) | |
| Chromosome 14 | ||||
| Normal | 15 (55%) | 19 (61%) | 34(59%) | |
| del(14q) | 4 (15%) | 1 (3%) | NS | 5 (9%) |
| Polysomy | 8 (30%) | 11 (36%) | 19 (32%) | |
| Chromosome 17 | ||||
| Normal | 5 (19%) | 20 (65%) | 25 (43%) | |
| del(17p) | 20 (70%) | 6 (19%) | p<.001 | 26 (45%) |
| Polysomy | 2 (7%) | 5 (16%) | 7 (12%) | |
| Del(17p11.2) | 18 (67%) | 3 (10%) | p<.001 | 21 (36%) |
| Chromosmose 18 | ||||
| Normal | 13 (48%) | 17 (55%) | 30 (52%) | |
| del(18q) | 14 (52%) | 10 (32%) | NS | 29 (50%) |
| Polysomy | 0 (0%) | 4 (13%) | 4 (7%) | |
| Chromosome 20 | ||||
| Normal | 5 (19%) | 12 (39%) | 17 (27%) | |
| 20q+ | 17 (63%) | 12 (39%) | NS | 29 (50%) |
| Polysomy | 5 (19%) | 7 (22%) | 12 (21%) | |
| Chromosome 22 | ||||
| Normal | 15 (56%) | 23 (74%) | 38 (66%) | |
| del(22q) | 6 (22%) | 0 (0%) | p = .02 | 6 (10%) |
| Polysomy | 6 (22%) | 8 (26%) | 14 (24%) |
Results expressed as number of cases and percentage of cases between brackets; NS: statistically not significant (p>.05).